ECSP22077299A - Inhibidores alostéricos de cromenona del fosfoinosítido 3-quinasa (pi3k) para el tratamiento de enfermedades asociadas con modulación del pi3k - Google Patents

Inhibidores alostéricos de cromenona del fosfoinosítido 3-quinasa (pi3k) para el tratamiento de enfermedades asociadas con modulación del pi3k

Info

Publication number
ECSP22077299A
ECSP22077299A ECSENADI202277299A ECDI202277299A ECSP22077299A EC SP22077299 A ECSP22077299 A EC SP22077299A EC SENADI202277299 A ECSENADI202277299 A EC SENADI202277299A EC DI202277299 A ECDI202277299 A EC DI202277299A EC SP22077299 A ECSP22077299 A EC SP22077299A
Authority
EC
Ecuador
Prior art keywords
pi3k
phosphoinositide
kinase
modulation
treatment
Prior art date
Application number
ECSENADI202277299A
Other languages
English (en)
Inventor
David L Mcelligott
Daniel Lee Severance
Thomas Combs Irvin
Katelyn Frances Long
Johnathan Alexander Mclean
Manoj Kumar
Gabrielle R Kolakowski
Michael Brian Welch
Aleksey I Gerasyuto
Loredana Puca
Eugene R Hickey
Nicholas A Boyles
Kannan Karukurichi Ravi
Jennifer Lynn Knight
Tien Widjaja
Anke Klippel-Giese
Edward A Kesicki
Sean Douglas Aronow
Markus K Dahlgren
Shulu Feng
Erin Danielle Anderson
Christopher Glenn Mayne
Original Assignee
Petra Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Petra Pharma Corp filed Critical Petra Pharma Corp
Publication of ECSP22077299A publication Critical patent/ECSP22077299A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La descripción se refiere a los compuestos de la Fórmula (I) como inhibidores alostéricos de cromenona del fosfoinosítido 3-quinasa (PI3K) útiles en el tratamiento de enfermedades o trastornos asociados con la modulación del PI3K, Fórmula (I): o un profármaco, solvato, enantiómero, estereoisómero, tautómero o sal farmacéuticamente aceptable de este, en donde R1, R2, R3, R4, R5, R6, R7, R8, R9, W, X, Y, s, y el Anillo A son como se describen en la presente descripción.
ECSENADI202277299A 2020-04-03 2022-10-03 Inhibidores alostéricos de cromenona del fosfoinosítido 3-quinasa (pi3k) para el tratamiento de enfermedades asociadas con modulación del pi3k ECSP22077299A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202063005096P 2020-04-03 2020-04-03

Publications (1)

Publication Number Publication Date
ECSP22077299A true ECSP22077299A (es) 2023-01-31

Family

ID=75674963

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202277299A ECSP22077299A (es) 2020-04-03 2022-10-03 Inhibidores alostéricos de cromenona del fosfoinosítido 3-quinasa (pi3k) para el tratamiento de enfermedades asociadas con modulación del pi3k

Country Status (18)

Country Link
US (2) US11649227B2 (es)
EP (1) EP4126851A1 (es)
JP (1) JP7505023B2 (es)
KR (1) KR102857816B1 (es)
CN (1) CN115956075B (es)
AR (1) AR121719A1 (es)
AU (1) AU2021248415B2 (es)
BR (1) BR112022019918A2 (es)
CO (1) CO2022014160A2 (es)
CR (1) CR20220493A (es)
EC (1) ECSP22077299A (es)
IL (1) IL296918A (es)
JO (1) JOP20220247A1 (es)
MX (1) MX2022012306A (es)
PE (1) PE20230824A1 (es)
PH (1) PH12022552637A1 (es)
TW (1) TWI794780B (es)
WO (1) WO2021202964A1 (es)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR121719A1 (es) * 2020-04-03 2022-06-29 Petra Pharma Corp Inhibidores alostéricos de cromenona del fosfoinosítido 3-quinasa (pi3k) para el tratamiento de enfermedades
WO2022235575A1 (en) * 2021-05-03 2022-11-10 Petra Pharma Corporation Allosteric chromenone inhibitors of phosphoinositide 3-kinase (pi3k) for the treatment of disease
KR20240004865A (ko) 2021-05-03 2024-01-11 페트라 파마 코포레이션 질환의 치료를 위한 포스포이노시티드 3-키나제 (pi3k)의 알로스테릭 크로메논 억제제
CN117769546A (zh) * 2021-05-27 2024-03-26 佩特拉制药公司 用于治疗疾病的磷酸肌醇3-激酶(pi3k)的变构色烯酮抑制剂
EP4347040A1 (en) 2021-05-27 2024-04-10 Petra Pharma Corporation Allosteric chromenone inhibitors of phosphoinositide 3-kinase (pi3k) for the treatment of cancer
TW202329930A (zh) 2021-09-30 2023-08-01 美商佩特拉製藥公司 用於治療疾病之磷酸肌醇3-激酶(pi3k)之異位色烯酮抑制劑
CA3232906A1 (en) * 2021-10-07 2023-04-13 Alessandro Boezio Pi3k-alpha inhibitors and methods of use thereof
WO2023081209A1 (en) * 2021-11-03 2023-05-11 Zeno Management, Inc. Pi3k inhibitors and methods of treating cancer
WO2023104111A1 (en) * 2021-12-08 2023-06-15 Nanjing Zenshine Pharmaceuticals Co., Ltd. Fused heterocyclic compounds as pi3kalpha inhibitors
AU2022421224A1 (en) * 2021-12-22 2024-06-20 The Regents Of The University Of California Covalently binding inhibitors of g12s, g12d and/or g12e mutants of k-ras gtpase
US20240124422A1 (en) * 2022-03-29 2024-04-18 Prelude Therapeutics Incorporated Mutant pi3k-alpha inhibitors and their use as pharmaceuticals
TW202404968A (zh) * 2022-04-20 2024-02-01 美商思諾維新醫藥公司 ＰＩ３Ｋα抑制劑
US20250263394A1 (en) * 2022-04-24 2025-08-21 InventisBio Co., Ltd. Compounds, preparation methods and uses thereof
US20240018115A1 (en) * 2022-04-29 2024-01-18 Petra Pharma Corporation Allosteric chromenone inhibitors of phosphoinositide 3-kinase (pi3k) for the treatment of disease
IL316619A (en) * 2022-05-10 2024-12-01 Relay Therapeutics Inc PI3Kα inhibitors and methods of using them
IL317360A (en) 2022-06-08 2025-01-01 Onkure Inc Benzopyrimidines-(3H)4ONE as PI3K inhibitors
CN117384124B (zh) * 2022-07-04 2025-08-01 安徽中医药大学 Hdac抑制剂、组合物及其应用
CN117362281A (zh) * 2022-07-07 2024-01-09 海创药业股份有限公司 一种pi3k抑制剂及其制备方法和用途
CN120265619A (zh) 2022-09-08 2025-07-04 恩库勒公司 作为pi3k抑制剂的异喹诺酮
CN119894898A (zh) * 2022-09-09 2025-04-25 益方生物科技(上海)股份有限公司 化合物、其制备方法和用途
WO2024064024A1 (en) 2022-09-19 2024-03-28 Onkure, Inc. ((4-oxo-3,4-dihydroquinazolin-8-yl)methyl)amine derivatives as p13k inhibitors for the treatment of cancer
WO2024081904A1 (en) * 2022-10-14 2024-04-18 Genesis Therapeutics, Inc. Methods for treating cancer
WO2024081345A1 (en) 2022-10-14 2024-04-18 Onkure, Inc. Benzopyrimidin-4(3h)-ones as pi3k inhibitors
WO2024086789A2 (en) * 2022-10-20 2024-04-25 Prelude Therapeutics Incorporated Mutant pi3k-alpha inhibitors and their use as pharmaceuticals
CN120858094A (zh) * 2022-11-01 2025-10-28 佩特拉制药公司 用于治疗疾病的磷酸肌醇3-激酶(pi3k)的变构色烯酮抑制剂
WO2024097721A1 (en) 2022-11-02 2024-05-10 Petra Pharma Corporation Targeting allosteric and orthosteric pockets of phosphoinositide 3-kinase (pi3k) for the treatment of disease
AU2023373670A1 (en) * 2022-11-02 2025-05-15 Petra Pharma Corporation Allosteric chromenone inhibitors of phosphoinositide 3-kinase (pi3k) for the treatment of disease
WO2024099437A1 (en) * 2022-11-11 2024-05-16 Fochon Biosciences, Ltd. Compounds as protein kinase inhibitors
WO2024163752A1 (en) * 2023-02-02 2024-08-08 Synnovation Therapeutics, Inc. HETEROCYCLIC COMPOUNDS AS PI3Kα INHIBITORS
JP2026510901A (ja) * 2023-03-15 2026-04-10 エーエヌ２ セラピューティックス，インコーポレイテッド 化学化合物
WO2024211346A1 (en) * 2023-04-03 2024-10-10 Prelude Therapeutics Incorporated Mutant pi3k-alpha inhibitors and their use as pharmaceuticals
KR20260005985A (ko) 2023-05-05 2026-01-12 일라이 릴리 앤드 캄파니 Er+ 유방암을 갖는 대상체에서 중추 신경계 (cns) 전이를 치료 및 예방하는 데 사용하기 위한 임루네스트란트 또는 그의 염
IL325232A (en) * 2023-06-21 2026-02-01 Regor Pharmaceuticals Inc PI3K inhibitors and their use
WO2025007074A1 (en) * 2023-06-30 2025-01-02 Reactive Biosciences, Inc. Chemical compounds
WO2025026442A1 (zh) * 2023-08-02 2025-02-06 郑州同源康医药有限公司 稠环类化合物及其用途
AU2024325407A1 (en) 2023-08-11 2026-02-19 Onkure Therapeutics, Inc. Benzopyridinones and benzopyrimidinones as pi3k inhibitors
WO2025042896A1 (en) * 2023-08-22 2025-02-27 Mayo Foundation For Medical Education And Research DNA TOPOISOMERASE IIβ INHIBITORS
CN119874676A (zh) * 2023-10-25 2025-04-25 海创药业股份有限公司 一种pi3k抑制剂及其制备方法和用途
WO2025207755A1 (en) 2024-03-29 2025-10-02 Onkure, Inc. Quinolizinones as pi3k inhibitors
WO2025212360A1 (en) 2024-04-01 2025-10-09 Onkure, Inc. Isoquinolones as pi3k inhibitors
WO2025231053A1 (en) * 2024-05-01 2025-11-06 Petra Pharma Corporation Solid forms of 6-chloro-3-[(1r)-1-[3,6-dimethyl-2-(2-methylindazol-5-yl)-4-oxo-chromen-8-yl]ethoxy]pyridine-2-carboxamide
WO2025231052A1 (en) * 2024-05-01 2025-11-06 Petra Pharma Corporation Solid dispersions of 6-chloro-3-[(1r)-1-[3,6-dimethyl-2-(2- methylindazol-5-yl)-4-oxo-chromen-8-yl]ethoxy]pyridine-2-carboxamide
WO2025255233A1 (en) 2024-06-07 2025-12-11 Onkure, Inc. Compounds containing fused tricyclic rings as pi3k inhibitors

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1190405B (it) 1985-10-22 1988-02-16 Recordati Chem Pharm Derivati del flavone
IL89840A (en) 1988-04-06 1996-10-31 Lipha Substituted flavonoid compounds and salts thereof their preparation and pharmaceutical composition containing them
HUT58310A (en) 1988-12-21 1992-02-28 Upjohn Co Anti-atherosclerotic and anti-thrombotic 1-benzopyran-4-one- and 2-amino-1,3-benzoxazin-4-one derivatives, process for producing them and pharmaceutical compositions containing them
US5763263A (en) 1995-11-27 1998-06-09 Dehlinger; Peter J. Method and apparatus for producing position addressable combinatorial libraries
EP1857443B1 (en) 2000-01-24 2012-03-28 AstraZeneca AB Therapeutic morpholino-substituted compounds
WO2003035066A1 (en) * 2001-10-23 2003-05-01 Celltech R & D Limited 2-aminoquinolone derivatives for use as impdh inhibitors
US7884127B2 (en) 2002-07-08 2011-02-08 Pirimal Life Sciences Ltd. Inhibitors of cyclin dependent kinases and their use
TWI331034B (en) 2002-07-08 2010-10-01 Piramal Life Sciences Ltd Inhibitors of cyclin-dependent kinases and their use
JP4646626B2 (ja) 2002-08-16 2011-03-09 アストラゼネカ アクチボラグ ホスホイノシチド３−キナーゼβの阻害
CN100430389C (zh) * 2002-08-16 2008-11-05 阿斯利康(瑞典)有限公司 抑制磷酸肌醇3-激酶β
AU2009295948B2 (en) 2008-09-29 2013-12-05 GlaxoSmithKline, LLC Quinazolinone, quinolone and related analogs as sirtuin modulators
US8399460B2 (en) * 2009-10-27 2013-03-19 Astrazeneca Ab Chromenone derivatives
SG10201500895XA (en) * 2009-11-05 2015-04-29 Rhizen Pharmaceuticals Sa Chromen-4-one Derivatives As Kinase Modulators
US8530470B2 (en) * 2011-04-13 2013-09-10 Astrazeneca Ab Chromenone derivatives
CN106008479B (zh) * 2015-03-06 2020-01-10 南京圣和药业股份有限公司 作为磷脂酰肌醇3-激酶δ抑制剂的取代嘧啶类化合物及其应用
EP3426242A4 (en) 2016-03-11 2020-03-18 H. Lee Moffitt Cancer Center And Research Institute, Inc. ICARIIN AND ICARITIN DERIVATIVES
CN108299365B (zh) 2018-01-31 2021-08-06 中南大学 一种黄酮衍生物及其应用
AR121719A1 (es) 2020-04-03 2022-06-29 Petra Pharma Corp Inhibidores alostéricos de cromenona del fosfoinosítido 3-quinasa (pi3k) para el tratamiento de enfermedades

Also Published As

Publication number Publication date
IL296918A (en) 2022-12-01
US20220372023A1 (en) 2022-11-24
CN115956075B (zh) 2025-11-07
JP2023521321A (ja) 2023-05-24
WO2021202964A1 (en) 2021-10-07
MX2022012306A (es) 2023-01-04
BR112022019918A2 (pt) 2023-02-14
EP4126851A1 (en) 2023-02-08
CR20220493A (es) 2022-12-15
CA3173569A1 (en) 2021-10-07
JOP20220247A1 (ar) 2023-01-30
AR121719A1 (es) 2022-06-29
AU2021248415B2 (en) 2024-03-21
JP7505023B2 (ja) 2024-06-24
AU2021248415A1 (en) 2022-10-20
PH12022552637A1 (en) 2023-01-16
CN115956075A (zh) 2023-04-11
CO2022014160A2 (es) 2023-02-16
TWI794780B (zh) 2023-03-01
TW202200567A (zh) 2022-01-01
PE20230824A1 (es) 2023-05-19
KR102857816B1 (ko) 2025-09-11
US20230286960A1 (en) 2023-09-14
KR20220163462A (ko) 2022-12-09
US11649227B2 (en) 2023-05-16

Similar Documents

Publication Publication Date Title
CO2022014160A2 (es) Inhibidores alostéricos de cromenona del fosfoinosítido 3-quinasa (pi3k) para el tratamiento de enfermedades asociadas con la modulación de p13k
DOP2023000245A (es) Inhibidores alostéricos de cromenona del fosfoinosítido 3-quinasa (pi3k) para el tratamiento de enfermedades
MX2024003721A (es) Inhibidores alostericos de cromenona de la fosfoinositido 3-quinasa (pi3k) para el tratamiento de enfermedades.
MX2023013987A (es) Inhibidores alostéricos de cromenona de la fosfoinosítido 3-quinasa (pi3k) para el tratamiento contra el cáncer.
CL2022001739A1 (es) Compuestos tricíclicos sustituidos
DOP2025000245A (es) Inhibidores de kras
UY37900A (es) Nuevos derivados de rapamicina
MX394700B (es) Inhibidores de mnk sustituidos con piperidina y métodos relacionados con los mismos.
CO2019000932A2 (es) Nuevos compuestos sulfonimidoilpurinona 7-sustituidos y derivados para el tratamiento y la profilaxis de la infección vírica.
UY35551A (es) Derivados heteroarilos como inhibidores de aldosterona sintasa
MX2021003945A (es) Compuestos de indolinona para uso como inhibidores de map4k1.
AR115731A1 (es) Derivados de pirrolo[1,2-b]piridazina como inhibidores de quinasas irak4
CO2020010306A2 (es) Compuestos de sulfonimidoilpurinona 7-sustituida y derivados para el tratamiento y profilaxis de cáncer de hígado.
CL2022002975A1 (es) Compuestos y composiciones para inhibir la actividad de hif2-alfa y sus métodos de uso
CO2025003099A2 (es) Compuestos para el tratamiento del cáncer
MX2024003028A (es) Derivados de 6 aza quinolina y usos relacionados.
CO2025011377A2 (es) Derivados de hidroquinazolina para el tratamiento de una enfermedad o un trastorno
DOP2025000216A (es) Derivados de fenilpiperidina como inhibidores de la glutaminil-péptido ciclotransferasa y proteína similar a glutaminil-péptido ciclotransferasa
MX2025005073A (es) Inhibidores alostericos de cromenona de la fosfoinositido 3-quinasa (pi3k) para el tratamiento de enfermedades
CL2022002697A1 (es) Inhibidores alostéricos de cromenona del fosfoinosítido 3-quinasa (pi3k) para el tratamiento de enfermedades
AR131414A1 (es) Inhibidores de la proteína tirosina fosfatasa, composiciones y métodos de uso
AR130937A1 (es) Inhibidores alostéricos de cromenona del fosfoinosítido 3-quinasa (pi3k) para el tratamiento de enfermedades
AR125979A1 (es) Inhibidores alostéricos de cromenona de la fosfoinositido 3-quinasa (pi3k) para el tratamiento de enfermedades
AR125742A1 (es) Inhibidores alostéricos de cromenona de la fosfoinositida 3-quina6sa (pi3k) para el tratamiento de enfermedades
AR119280A1 (es) Compuestos de 2,3-dihidroquinazolina como inhibidores nav1.8